Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data In Difficult-To-Treat Plaque Psoriasis With Proven Durability Through 2-Years, Affirming Its Use As A Powerful First Line Systemic Therapy

By Reuters News

Oct 2 (Reuters) - Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON ANNOUNCES NEW ICOTYDE® (ICOTROKINRA) DATA IN DIFFICULT-TO-TREAT PLAQUE PSORIASIS WITH PROVEN DURABILITY THROUGH 2-YEARS, AFFIRMING ITS USE AS A POWERFUL FIRST LINE SYSTEMIC THERAPY~

  • J&J - 60% SCALP PSORIASIS, 89% GENITAL PSORIASIS PATIENTS ACHIEVE COMPLETE CLEARANCE AT WEEK 112

  • J&J - SAFETY FINDINGS THROUGH WEEK 112 CONSISTENT WITH ICOTYDE PROFILE, NO NEW SAFETY SIGNALS

  • J&J - ICOTYDE-TREATED PATIENTS SHOW 70% CLEAR OR ALMOST CLEAR SKIN AT WEEK 112

Further company coverage: JNJ.N

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.